Strategies to Increase the Value of Drug Therapy

Strategies to Increase the Value of Drug Therapy

Value is a concept that concerns all healthcare stakeholders.

Five things for pharma marketers to know: Friday, March 27

Five things for pharma marketers to know: Friday, March 27

Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system

Diabetes diagnoses jumped as a result of healthcare reform

Diabetes diagnoses jumped as a result of healthcare reform

Diagnoses spiked in states with expanded Medicaid programs. This may mean higher prescription rates, but research shows a lack of diagnoses also has a price.

Shire and Cincinnati Children's Hospital team up in rare diseases

Shire and Cincinnati Children's Hospital team up in rare diseases

The duo hope to begin testing a new treatment within three years.

Researchers say testosterone ads amount to disease mongering

An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.

Five things for pharma marketers to know: Thursday, March 26

Five things for pharma marketers to know: Thursday, March 26

Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk

Physicians call for emphasis on women's health research and care

Physicians call for emphasis on women's health research and care

Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.

Implement a Direct-to-Patient Approach to Increase Patient Engagement and Retention

Implement a Direct-to-Patient Approach to Increase Patient Engagement and Retention

Direct-to-patient approaches can positively impact real world and late phase research programs to increase engagement, retention and data collection.

Bristol-Myers Squibb licenses autoimmune program from Novo Nordisk

The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.

Five things for pharma marketers to know: Wednesday, March 25

Five things for pharma marketers to know: Wednesday, March 25

Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.

Doctors want specifics on biosimilar labels

An Alliance for Safe Biologic Medicines survey shows what doctors mean by biosimilar transparency.

Five things for pharma marketers to know: Tuesday, March 24

Five things for pharma marketers to know: Tuesday, March 24

Angelina Jolie Pitt discloses she had her fallopian tubes and ovaries removed; the FDA's Zyprexa investigation was inconclusive; Takeda and ImmunoGen sign a $20-million deal

Pharma DTC spending jumps almost 21% in 2014

Pharma DTC spending jumps almost 21% in 2014

Nielsen data shows pharma spent $4.5 billion on DTC ads last year.

Opioid deterrence may work, labeling rules are coming

Opioid deterrence may work, labeling rules are coming

A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.

Harrison and Star names co-president

Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.

Baby boomers are no healthier than others

A study shows that greater access to healthcare and lower smoking rates have not made baby boomers healthier than their parents.

Five things for pharma marketers to know: Monday, March 23

Five things for pharma marketers to know: Monday, March 23

Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases

Five things for pharma marketers to know: Friday, March 20

Five things for pharma marketers to know: Friday, March 20

A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik

ASCO wants to talk value when talking cancer

ASCO wants to talk value when talking cancer

An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.

The Patient Abroad: An Exploration of the Motivations and Impact of Medical Tourism

The Patient Abroad: An Exploration of the Motivations and Impact of Medical Tourism

As global healthcare borders become increasingly blurred, the internationally mobile patient may become a standard patient segment considered in healthcare market research.

Sanofi R&D lead takes aim at global drug regulations

The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

US pharma market value projected to be $550 billion in five years

US pharma market value projected to be $550 billion in five years

Oncology and diabetes medications are expected to be major areas of growth.

What's Your Connected Health Strategy?

What's Your Connected Health Strategy?

At SXSW, for the first time, health wasn't a breakout topic, but rather a "break-in" topic that had the attention of just about every presenter and attendee.

Medtronic teams up with Glooko

The diabetes device manufacturer will soon work with Glooko's platform.

Pfizer takes issue with Little Remedies

The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.

Five things for pharma marketers to know: Wednesday, March 18

Five things for pharma marketers to know: Wednesday, March 18

GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data

23andMe will harness genetic research in new drug discovery unit

23andMe will harness genetic research in new drug discovery unit

The personal genetics company created a therapeutics group to extricate new drug targets from its research database.

Customizing HCP Data In a Challenging Healthcare Environment

Customizing HCP Data In a Challenging Healthcare Environment

Traditional tactics of connecting with physicians are quickly becoming obsolete.

Obesity medications still a hard sell

Increased FDA scrutiny has not garnered trust for the new medications.

Five things for pharma marketers to know: Tuesday, March 17

Five things for pharma marketers to know: Tuesday, March 17

Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing

PCSK9 drugs show viability, tolerability

PCSK9 drugs show viability, tolerability

Amgen and Sanofi/Regeneron shared clinical trial data that shows PCSK9 inhibitors dropped LDL levels by around 60%.

FDA approves Boston Scientific atrial fibrillation device

The approval follows three advisory panel reviews and a complete response letter.

Five things for pharma marketers to know: Monday, March 16

Five things for pharma marketers to know: Monday, March 16

New data suggest Amgen's PCSK9 may reduce risks of heart attacks, Salix bidding is war too rich for Endo's blood, Actavis bipolar drug use is expanded to 10- to 17-year-olds.

Five things for pharma marketers to know: Friday, March 13

Five things for pharma marketers to know: Friday, March 13

J&J sues GlaxoSmithKline over Flonase ads, CDC report finds patients with invasive cancer are living for five years or longer have diagnosis, and Bristol-Myers Squibb resubmits its HCV treatment.

Biosimilar uptake will require companies to tell a trustworthy backstory

Biosimilar uptake will require companies to tell a trustworthy backstory

Reactions to the first biosimilar approval show that marketing and education will be essential for the new category to take market share.

Data on investigational cholesterol-lowering meds to be presented at cardiology meeting

The research will be released as pharmacy benefit managers raise concerns about the potential costs of PCSK9 inhibitors.

CVS exec: biosimilars could discount expensive meds by 40% to 50%

The CMO of CVS Health said biosimilars could drive down prices 10% to 20% lower than current investor expectations.

Five things for pharma marketers to know: Thursday, March 12

Five things for pharma marketers to know: Thursday, March 12

The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.

Endo makes better offer for Salix

Endo makes better offer for Salix

The company argues its offer for Salix is superior to the terms offered by serial acquirer Valeant.

The Next Disruptor of Clinical Trials? Try Apple

The Next Disruptor of Clinical Trials? Try Apple

Apple now offers a way for researchers and developers to easily create clinical trial data-collection apps, revolutionizing the way that patients can participate in clinical trials.

AstraZeneca, Joslin Diabetes Center ink three-year collaboration

The partners will focus on developing treatments for metabolic disorders.

Five things for pharma marketers to know: Wednesday, March 11

Five things for pharma marketers to know: Wednesday, March 11

Zogenix spins off painkiller business; Biogen Idec investigates the use of wearables in MS patients; J&J sues Celltrion and Hospira to delay Remicade biosimilar.

Report: US drug spending jumped 13% in 2014

Report: US drug spending jumped 13% in 2014

PBM Express Scripts said last year's trends reflect a major shift in how the pharmaceutical industry does business and that generics are not the bargain they once were.

FDA letter focuses on UCLA claims about an unapproved diagnostic

The agency's Office of Prescription Drug Promotion said a website indicated safety and effectiveness of a diagnostic tool that has not been approved by the FDA.

Five things for pharma marketers to know: Tuesday, March 10

Five things for pharma marketers to know: Tuesday, March 10

HCV drugs and other specialty medications drove a 13% increase in last year's prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera's drug that can reduce double chins.

Evolving views of obesity raise questions about the role of weight-loss drugs

Evolving views of obesity raise questions about the role of weight-loss drugs

Doctors tell MM&M that prescription weight-loss medications are just one component of an obesity treatment regimen.

Apple launches software platform for medical research

The open-source framework uses the iPhone's apps to gather users' health information.

Five things for pharma marketers to know: Monday, March 9

Five things for pharma marketers to know: Monday, March 9

Novartis CEO says cost cutting is looming; Novo Nordisk presents new Saxenda weight-loss data; FDA approves Astellas Pharma's antifungal drug.

FDA hands Amgen a biosimilar competitor

FDA hands Amgen a biosimilar competitor

The regulator approved Novartis's Neupogen lookalike. Amgen, which markets Neupogen, has a trove of its own potential biosimilars.

Five things for pharma marketers to know: Friday, March 6

Five things for pharma marketers to know: Friday, March 6

FDA approves the first biosimilar, judge rules that FDA panel members had conflicts of interest, and a new venture will evaluate the effectiveness of digital health technologies.

Imbruvica eases AbbVie's patent worries

Imbruvica eases AbbVie's patent worries

AbbVie's $21-billion bid to acquire Pharmacyclics may insulate the drugmaker from the impact of impending Humira biosimilars.

Tufts: biosimilars will not be an instant hit

A study by the nonprofit research group found resistance to drug switching.

Accenture survey finds lacking alignment between pharma IT and marketing

The move toward digital will likely bring greater collaboration between CMOs and CIOs.

Eisai and Merck make cancer research pact

The drugmakers will explore combinations of Merck's Keytruda and Eisai's Lenvima and Halaven to treat certain cancers.

Five things for pharma marketers to know: Thursday, March 5

Five things for pharma marketers to know: Thursday, March 5

AbbVie nabs Pharmacyclics for $21 billion, Mallinckrodt makes a Pfizer-Hospira style acquisition, and the National Cancer Institute's director resigns

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

The FDA granted the drug Priority Review status just last week.

Orexigen pleases shareholders, irks FDA

The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.

Researchers find safety disclaimers do not register with consumers

The study indicates patients discount wording that indicates the FDA has not approved supplement claims.

Safety advocate, DOJ settle kickback allegations

The agreement includes a $1-million payment.

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

Holding company will now focus on two health networks—FCB Health and McCann Health

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Amgen results for Kyprolis could sideline Velcade

Amgen results for Kyprolis could sideline Velcade

Analysts say head-to-head study results could make Kyprolis the lead treatment.

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Drugmakers face increasing pressure on pricing from insurers and PBMs.

Pradaxa antidote goes to FDA

The breakthrough designation therapy drug was the first for its drug class.

GAO: Dementia patients receiving harmful antipsychotics

Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.

Five things for pharma marketers to know: Monday, March 2

Five things for pharma marketers to know: Monday, March 2

Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.

Five things for pharma marketers to know: Friday, February 27

Five things for pharma marketers to know: Friday, February 27

Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.

PCORI explains how it will release comparative-effectiveness findings

PCORI explains how it will release comparative-effectiveness findings

The organization plans to publish a scientific and a lay abstract detailing study findings

Sanofi's new Lantus may not be the new Lantus

Sanofi's new Lantus may not be the new Lantus

Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.

Drugmaker shifts sales model to keep pace with formulary decision making

Drugmaker shifts sales model to keep pace with formulary decision making

Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.

Concerns over Vyvanse marketing: NYT

A report by the New York Times, citing a lack of an advisory committee for Vyvanse and illegal marketing lawsuits resolved last year, expressed concerns that the drug for binge-eating disorder will be overprescribed.

BI rare-disease awareness push slated for Saturday

Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.

Lilly Lantus biosimilar to hit EU

The EU will have access to the new medication in May.

CDC finds patients using more potent opioids

The survey shows the use of stronger-than-morphine painkillers has jumped.

Five things for pharma marketers to know: Thursday, February 26

Five things for pharma marketers to know: Thursday, February 26

Sanofi's Lantus predecessor nabs approval; Pharmacyclics reportedly vets acquisition offers; FDA biosimilar hearing is postponed.

Poll shows all ages seek digital health tools

Poll shows all ages seek digital health tools

Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.

Mobile carries WebMD forward

Mobile carries WebMD forward

Smartphones drove network traffic.

GSK re-launches OTC diet pill

The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.

Five things for pharma marketers to know: Wednesday, February 25

Five things for pharma marketers to know: Wednesday, February 25

J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.

Global cancer drug market to grow to $111 billion by 2020: report

Global cancer drug market to grow to $111 billion by 2020: report

The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.

California ponders drug pricing reveal

Assemblyman David Chiu's bill would publish a drug's R&D and related costs.

UK doctors lobby for off-label Avastin use

Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.

Five things for pharma marketers to know: Tuesday, February 24

Five things for pharma marketers to know: Tuesday, February 24

FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.

Lilly peglispro delay may be boon for its biosimilar

Lilly peglispro delay may be boon for its biosimilar

The drugmaker wants to put the drug through additional liver-impact tests.

Survey shows docs shrug off Sunshine

A MedPanel survey indicates doctors have not changed their business practices since the Open Payments database went live.

AdAge: advertising's penalty box is empty

The Trustworthy Accountability of National Advertisers launched its naming-names initiative in November, but the list is empty.

Five things for pharma marketers to know: Monday, February 23

Five things for pharma marketers to know: Monday, February 23

Valeant grabs Salix for $10.4 billion, BMS inks to collaborations deals and Pfizer lines up to have the first treatment for a rare lung disease.

Five things for pharma marketers to know: Friday, February 20

Five things for pharma marketers to know: Friday, February 20

23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.

Poll highlights cholesterol knowledge gap

Poll highlights cholesterol knowledge gap

Americans may be taking anti-cholesterol medications, but it doesn't mean they are aware of their impact.

Study shows Lucentis at Eylea disadvantage

Study shows Lucentis at Eylea disadvantage

An NIH study shows possible limit to Lucentis's appeal.

McNeil consumer president named HBA Woman of the Year

The Healthcare Businesswomen's Association named Denice Torres, president of J&J's McNeil Consumer Healthcare, as its 26th Woman of the Year.

Five things for pharma marketers to know: Thursday, February 19

Five things for pharma marketers to know: Thursday, February 19

Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.

FDA expands Revlimid indication

Celgene's cancer drug is now approved for newly diagnosed patients.

AstraZeneca may give critic a seat at the table

Scientist Cori Bargmann's Twitter history makes the nomination a bit of a surprise.

Five things for pharma marketers to know: Wednesday, February 18

Five things for pharma marketers to know: Wednesday, February 18

Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.

Survey shows docs overestimate adherence

Survey shows docs overestimate adherence

A small physician survey shows doctors think their patients have higher adherence rates than the norm.

Specialty medications have PBMs on edge

Specialty medications have PBMs on edge

CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.

Court invalidates patent for AstraZeneca asthma drug

A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters